Mineralys TherapeuticsMLYS
MLYS
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
159% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 17
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
6% more capital invested
Capital invested by funds: $540M [Q3] → $572M (+$31.6M) [Q4]
4.06% more ownership
Funds ownership: 89.29% [Q3] → 93.35% (+4.06%) [Q4]
1% more funds holding
Funds holding: 106 [Q3] → 107 (+1) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]
88% less call options, than puts
Call options by funds: $1K | Put options by funds: $8K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
73%
upside
Avg. target
$27
95%
upside
High target
$30
117%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Matthew Caufield 33% 1-year accuracy 21 / 63 met price target | 117%upside $30 | Buy Reiterated | 10 Mar 2025 |
Goldman Sachs Richard Law 60% 1-year accuracy 6 / 10 met price target | 73%upside $24 | Buy Maintained | 13 Feb 2025 |
Financial journalist opinion
Based on 14 articles about MLYS published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile –
Neutral
24/7 Wall Street
6 days ago
Insiders Make Huge Purchases of These 4 Biotech Stocks
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
Neutral
GlobeNewsWire
1 week ago
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension
Neutral
GlobeNewsWire
2 weeks ago
Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of the sale of an additional 1,944,444 shares of its common stock at a public offering price of $13.50 per share pursuant to the exercise in full of the underwriters' option to purchase additional shares in connection with Mineralys' recently completed public offering. After giving effect to the sale of these additional shares, the aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $201.2 million. All of the securities sold in the offering were sold by Mineralys.
Neutral
GlobeNewsWire
2 weeks ago
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25), which is being held in Chicago on March 29-31, 2025.
Negative
Benzinga
2 weeks ago
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday.
Neutral
GlobeNewsWire
3 weeks ago
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten public offering of 12,962,962 shares of its common stock at a public offering price of $13.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $175.0 million. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,944,444 shares of its common stock. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about March 13, 2025, subject to the satisfaction of customary closing conditions.
Positive
Seeking Alpha
3 weeks ago
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders.
Neutral
GlobeNewsWire
3 weeks ago
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. In addition, Mineralys expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Positive
Benzinga
3 weeks ago
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
On Monday, Mineralys Therapeutics, Inc. MLYS released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).
Charts implemented using Lightweight Charts™